Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Next Previous
Trial Profile

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ST 01156 (Primary)
  • Indications Ewing's sarcoma; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Seed Therapeutics

Most Recent Events

  • 29 Sep 2025 Status changed from planning to not yet recruiting.
  • 11 Aug 2025 According to SEED Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ST-01156. The clearance enables initiation of a first-in-human Phase 1 clinical trial in patients with advanced solid tumor and hematological malignancies, prioritizing multiple cancers with convincing preclinical evidence of RBM39 dependency. First patient dosing is expected in the first quarter of 2026.
  • 24 Apr 2025 According to SEED Therapeutics media release, SEED is rapidly transitioning into a clinical-stage company, with the planned IND filing for ST-01156 in the middle of this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top